Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against GSK plc. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GSK plc (“GSK” or “the Company”) (NYSE: GSK). Investors who purchased GSK securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether GSK has violated federal securities laws.
Investigation Details
On July 17, 2025, GSK issued a press release announcing “that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.” On this news, GSK’s American Depositary Receipt (“ADR”) price fell $1.81 per share, or 4.73%, to close at $36.47 per share on July 17, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased GSK securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
GSK — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”